Enveric Biosciences, Inc.
ENVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 93.5% and free cash flow fell 29.3%, each against the same quarter a year earlier.
Follow ENVB
Enveric Biosciences, Inc. (ENVB) EV/Sales
As of 16 October 2026, Enveric Biosciences, Inc. (ENVB) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −0.1× (March 2026) to 57,127,383× (December 2015); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 18.5× | 15,515.05% |
| FY2018 | 0.1× | (100.00%) |
| FY2017 | 12,862,076× | (59.52%) |
| FY2016 | 31,776,180× | (34.91%) |
| FY2015 | 48,817,400× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2020 | 14.8× | 5.58% |
| Jun 2020 | 14.0× | 71.08% |
| Mar 2020 | 8.2× | (55.66%) |
| Dec 2019 | 18.5× | 223.77% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVGN Evogene Ltd. compare | −2.8× |
| ENVB Enveric Biosciences, Inc. | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| LEXX Lexaria Bioscience Corp. compare | 2.4× |
| IMNN Imunon, Inc. compare | 8.0× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)